DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 241.8

Change

+1.75 (+0.73)%

Market Cap

USD 0.15B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.01 (-0.03%)

USD 115.48B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 95.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 88.54B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.03 (+0.12%)

USD 75.49B
EUNL:F iShares Core MSCI World UCITS ..

-0.24 (-0.25%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.15 (-0.07%)

USD 56.16B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.01 (+0.05%)

USD 56.02B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.05 (-0.05%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.09 (+0.09%)

USD 51.63B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.27% 90% A- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.27% 88% B+ 72% C
Trailing 12 Months  
Capital Gain 17.58% 75% C 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.58% 73% C 65% D
Trailing 5 Years  
Capital Gain 73.93% 85% B 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.93% 85% B 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 8.50% 74% C 70% C-
Dividend Return 8.50% 73% C 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.18% 70% C- 89% A-
Risk Adjusted Return 103.87% 99% N/A 97% N/A
Market Capitalization 0.15B 35% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.